The Strength Comparison in Numbers
The weight loss numbers tell a clear story. Wegovy produces 14.9% average weight loss at 68 weeks on the 2.4 mg dose. Retatrutide produces 28.3% at 80 weeks on the 12 mg dose. Retatrutide also produces about 30% weight loss in the highest-BMI subgroup. This makes retatrutide roughly twice as effective as Wegovy for average weight loss. But strength is not just about peak efficacy — it is also about tolerability and safety.
Beyond the Numbers
Wegovy is FDA approved, manufactured under cGMP, and covered by many insurance plans. Retatrutide is none of those things. The strength advantage in the clinical data is undeniable, but it comes at the cost of regulatory uncertainty. Wegovy users know exactly what they are injecting, how it was made, and what to expect. Retatrutide users are buying unapproved product from vendors with varying quality standards. For many people, the regulatory strength of Wegovy outweighs the pharmacological strength of retatrutide.
Leave a Reply